Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P F Conte

Showing results (81-90 of 200) with videos related to

Pageof 20
Sort By:
American Journal of Clinical Oncology|December 1, 1989
Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancerP Pronzato, E Campora, D Amoroso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2012
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysisM V Dieci, E Barbieri, F Piacentini, et al.
Breast Cancer Research and Treatment|November 1, 1990
Megestrol acetate: phase II study of a single daily administration in advanced breast cancerP Pronzato, F Brema, D Amoroso, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Prediction of survival by thymidine labelling index in patients with resistant ovarian carcinomaA Alama, F Merlo, S Chiara, et al.
Anticancer Research|February 24, 2001
p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimenA Gadducci, C Cianci, S Cosio, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 1996
Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: in vitro synergistic cytotoxicity and DNA-induced strand-breaksM Andreuccetti, G Allegrini, A Antonuzzo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 10, 2013
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patientsV Guarneri, M V Dieci, E Barbieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1996
Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patientsA Falcone, R Danesi, F Dargenio, et al.
European Journal of Clinical Pharmacology|February 27, 2003
Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case reportG Bocci, R Danesi, G Allegrini, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Tumour kinetics, response to chemotherapy and survival in primary ovarian cancerA Alama, S Chiara, F Merlo, et al.
Pageof 20

Showing results (81-90 of 200) with videos related to

Sort By:
Pageof 20
American Journal of Clinical Oncology|December 1, 1989
Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancerP Pronzato, E Campora, D Amoroso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2012
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysisM V Dieci, E Barbieri, F Piacentini, et al.
Breast Cancer Research and Treatment|November 1, 1990
Megestrol acetate: phase II study of a single daily administration in advanced breast cancerP Pronzato, F Brema, D Amoroso, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Prediction of survival by thymidine labelling index in patients with resistant ovarian carcinomaA Alama, F Merlo, S Chiara, et al.
Anticancer Research|February 24, 2001
p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimenA Gadducci, C Cianci, S Cosio, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 1996
Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: in vitro synergistic cytotoxicity and DNA-induced strand-breaksM Andreuccetti, G Allegrini, A Antonuzzo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 10, 2013
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patientsV Guarneri, M V Dieci, E Barbieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1996
Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patientsA Falcone, R Danesi, F Dargenio, et al.
European Journal of Clinical Pharmacology|February 27, 2003
Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case reportG Bocci, R Danesi, G Allegrini, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Tumour kinetics, response to chemotherapy and survival in primary ovarian cancerA Alama, S Chiara, F Merlo, et al.
Pageof 20